1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shanghai Aladdin Biochemical Technology Co. Ltd. Class A

Shanghai Aladdin Biochemical Technology Co. Ltd. Class A

SSSE:688179
16.08
CNY
+0.17
(+1.07%)
0.44EPS
79.15P/E
10.03BMarket Cap
Oct 29Next Earn
Shanghai Aladdin Biochemical Technology Co. Ltd. Class A
SSE:688179
(Shanghai Stock Exchange)

Recent

price

16.08

P/E

ratio

79.15

div

yld

1.82%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.2
0.66
0.81
0.88
0.83
0.5
0.67
0.84
0.89
1.22
1.12
1.37
1.62
2.11
2.31
Revenue per Share
0.06
0.19
0.25
0.26
0.16
0.13
0.21
0.26
0.28
0.38
0.27
0.29
0.3
0.31
0.35
Basic EPS, GAAP
0.03
-0.28
0.14
-0.52
-0.14
0.09
0.11
0.2
0.27
-0.42
-0.31
0.03
0.35
1.07
- -
Free Cash Flow per Basic Share
- -
0.01
0.01
0.01
0.01
0.06
0.11
0.17
0.16
0.21
0.12
0.12
0.19
0.21
0.29
Dividend per Share
0.16
0.31
0.56
1.04
1.11
1.19
1.29
1.39
2.46
2.58
2.93
3.11
3.2
2.91
3.73
Book Value per Share
0.15
0.18
0.43
0.92
0.99
1.07
1.22
1.32
2.41
2.52
2.82
3.01
2.73
1.6
2.54
Tangible Book Value per Share
249
99
99
115
128
251
249
250
264
236
339
294
329
329
333
Basic Weighted Avg Shares
50
65
80
101
106
126
166
210
234
288
378
403
534
696
768
Sales/Revenue/Turnover
31.04
34.76
35.5
32.2
21.27
32.68
37.27
36.62
36.88
32.95
26.83
23.79
26.39
26.78
26.72
Operating Margin (%)
1
2
3
3
5
7
8
8
8
13
19
29
38
36
- -
Depreciation Expense
14
19
25
30
21
32
53
64
74
89
93
86
99
102
116
Net Income, GAAP
14.55
15.44
14.57
9.48
14.46
16.25
13.51
13.47
13.82
12.14
12.21
9.56
9.33
12.32
9.86
Effective Tax Rate (%)
27.6
28.64
30.54
29.38
19.49
25.27
32.12
30.39
31.78
31.06
24.54
21.3
18.51
14.67
15.17
Profit Margin (%)
25
23
68
130
107
120
138
165
635
574
969
1,011
914
830
798
Working Capital
- -
- -
- -
16
14
10
- -
- -
- -
9
333
344
390
661
296
LT Debt
40
78
139
260
278
296
323
346
817
858
975
1,036
1,143
1,163
1,556
Total Equity
- -
25.9
19.27
12.96
6.11
10.73
16.62
19.03
12.66
10.73
8.43
6.31
7.8
7.68
8.33
Return on Invested Capital (%)
- -
26.42
20.34
13.61
7.04
10.79
16.89
18.89
12.78
10.62
8.86
6.78
5.94
5.29
4.55
Return on Capital (%)
- -
31.63
22.51
14.9
7.65
11.15
17.28
19.04
12.8
10.67
10.12
8.54
9.39
10.03
9.63
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
110
124
163
LT Borrowings
647
644
270
LT Finance Leases
14
22
26
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
333
333
362
Market Capitalization
4,154
5,606
10,031

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,628
1,535
1,572
Cash, Cash Equivalents & STI
891
710
720
Accounts Receivable, Net
105
209
103
Inventories
531
561
576
Total Current Liabilities
798
717
774
Payables & Accruals
- -
- -
- -
ST Debt
110
124
163
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.26%
7.4%
1.73%
Free Cash Flow
75.43%
182.39%
203.1%
Net Income, GAAP
16.24%
6.96%
3.34%
Sales/Revenue/Turnover
21.69%
24.73%
30.39%
Total Cash Common Dividend
144.45%
15.61%
11.94%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
98
140
139
156
534
2025
130
145
- -
252
696
2026
171
200
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.09
0.08
0.08
0.3
2025
0.07
0.01
- -
0.13
0.31
2026
0.09
0.11
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.18
- -
- -
0.19
2025
0.09
0.11
- -
- -
0.21
2026
0.1
0.08
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shanghai Aladdin Biochemical Technology Co., Ltd. is a China-based manufacturer and distributor of scientific research reagents, life science materials, and laboratory consumables. Founded in 2009 and headquartered in Shanghai, China, the company develops, manufactures, and supplies high-purity scientific research products to academic institutions, universities, biopharmaceutical corporations, medical research laboratories, diagnostic developers, and industrial research and development enterprises across domestic and international markets. The company organizes its business operations across four core product divisions and a comprehensive laboratory consumables line: high-purity chemical reagents, including organic synthesis building blocks, organometallic catalysts, ligands, chemical synthesis reagents, chemical vapor deposition and atomic layer deposition precursors, analytical reference standards, and stable isotope reagents; life science products, comprising recombinant proteins, antibodies, molecular biology kits, cell biology reagents, GMP-grade raw materials for biomanufacturing, cell culture media, buffer components, and bioactive small molecules such as antibody-drug conjugates and proteolysis targeting chimeras; materials science supplies, encompassing electronic chemicals, advanced nanomaterials, battery and energy materials, and biomedical polymer composites; and laboratory consumables and instruments, marketed under its proprietary i-Quip brand, which includes automated and manual liquid handling systems, microcentrifuge tubes, PCR plastics, filtration and chromatography supplies, high-purity glassware, and personal protective laboratory equipment. The company distributes its product portfolio primarily through its integrated e-commerce platform, aladdin-e.com, supported by automated warehousing, regional logistics networks, and cold-chain distribution centers. In recent corporate developments, Shanghai Aladdin has expanded its domestic market footprint and accelerated its global operational presence. In March 2024, the company acquired a 51% controlling equity interest in Shanghai YuanYe Biotechnology Co., Ltd. for approximately RMB 181 million, substantially expanding its life science reagent portfolio, natural product library, and biochemical supply capabilities. To advance international expansion, the company established a direct operational footprint in Europe in late 2024 through its wholly owned subsidiary Aladdin Technology Limited by acquiring a corporate entity in Frankfurt, Germany, to establish localized sales, technical support, and warehousing distribution channels across the European market, complementing its existing overseas presence in North America. Additionally, the company has expanded its research, development, and production capacity with ongoing investments into specialized GMP-certified synthesis facilities and advanced quality testing laboratories.